Immuron in Research Agreement for Travelan With U.S. Defense Dept
12 Gennaio 2022 - 12:55PM
Dow Jones News
By Chris Wack
Immuron Ltd. said it was awarded 4.8 million Australian dollars
($3.4 million) in funding in a new research agreement with the U.S
Department of Defense a study to clinically evaluate a military
strength dosing regimen for Travelan.
The biopharmaceutical company said the U.S. Naval Medical
Research Center received A$1.4 million in funding to support the
Travelan clinical development effort.
The company said the focus of the new agreement is aimed at
testing and confirming the efficacy of a single larger dose regimen
of Travelan in a controlled human infection model clinical study
using the enterotoxigenic Escherichia coli strain H10407.
Immuron said this single larger dosing regime is potentially
more amenable for use in military populations. Up to 60 volunteers
will be enrolled in the clinical study and will be randomly
assigned to receive either a once-daily dose of 1200 mg of Travelan
or placebo.
Results of the proposed clinical study will also inform on
dosing in the pivotal Phase 3 registration trials for Biologics
License Application licensure. A project kickoff meeting for this
award has been scheduled for the end of January with the U.S
government sponsors.
The company said two company-sponsored clinical studies have
demonstrated that Travelan conferred 84% to more than 90%
protective efficacy against moderate to severe diarrhea upon
challenge with ETEC in comparison with a placebo. These clinical
studies were performed using two different doses of Travelan, 200
mg and 400 mg, administered three times a day. Ongoing discussions
with Army and Navy leadership have highlighted that such a regimen
is cumbersome for military personnel deployed in austere
environments and military field studies have shown that compliance
is low with products dosed more than once per day.
Immuron shares were up 48% to $3.87 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 12, 2022 06:40 ET (11:40 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Immuron (ASX:IMC)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Immuron (ASX:IMC)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Immuron Limited (Borsa Australiana): 0 articoli recenti
Più Immuron Limited Articoli Notizie